Douglas Warner
Chief Medical OfficerDr. Douglas Warner, also known as Doug, M.D., is Chief Medical Officer at Tyra Biosciences, Inc. from September 2024. He was Chief Medical Officer of eFFECTOR Therapeutics, Inc. from August 2022 until June 21, 2024. He was responsible for developing registration strategies for both programs and exploring expansion into additional oncology indications. Prior to eFFECTOR, he held roles of increasing responsibility at Amgen where he oversaw extensive clinical development programs in multiple indications across oncology and general medicine. In his position, Executive Medical Director, Group Product Area Lead, he provided development guidance and oversight over a broad portfolio of solid tumor immune-oncology and pathway inhibitor development programs that ranged from phase 1 to marketed products. Prior to this position, he was the Global Development Lead for several products including Vectibix, XGEVA and Prolia. He is co-author on numerous peer-reviewed articles including those in The Lancet, The Lancet Oncology and The Journal of Clinical Oncology. He received his B.A. from the University of Pennsylvania, his M.D. from the Duke University School of Medicine and his M.B.A. from the UCLA Anderson School of Management.
Positions
- Company NameTyra Biosciences, Inc.Stock CodeTYRAPositionChief Medical OfficerColleagues
- THTodd HarrisCo-Founder, CEO, President & Director
- BABhavesh AsharChief Operating Officer
- DBDaniel BensenCo-Founder & Chief Discovery Officer
- AFAlan FuhrmanChief Financial Officer
- RJRobert J. MoreIndependent Director
- RVRehan VerjeeIndependent Director
- SMSusan MoranIndependent Director
- JSJake SimsonIndependent Director
